Last reviewed · How we verify

NCT05436483

Preliminary Establishment of the Medical Reference Range of Serum Vitamin K2 in Chinese Healthy Adults

Status unknown Last updated 29 June 2022
What this trial tests

trial in Health, Subjective in 465 participants. Status unknown.

Timeline
31 July 2022
Primary endpoint
30 July 2023
31 August 2023

Quick facts

Lead sponsorPeking University Third Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment465
Start date31 July 2022
Primary completion30 July 2023
Estimated completion31 August 2023

Conditions studied

Sponsor

Peking University Third Hospital

Who can join

Adults 18 to 80, any sex, with Health, Subjective. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Osteocalcin is a type of vitamin K2-dependent protein, and many studies have confirmed that vitamin K2 has anti-osteoporosis effects, and has preventive and therapeutic effects on a variety of diseases such as nervous system, cardiovascular disease, immune disease, and glucose metabolism. However, as a pleiotropic vitamin and nutrient, vitamin K2 does not have an exact normal range like other vitamins, when it needs to be supplemented, and in what regimen. Different organizations have different opinions on the recommended intake of vitamin K. Thus, this study intends to preliminarily obtain the reference interval of serum vitamin K2 by conducting clinical research in healthy people in the Beijing-Tianjin-Hebei region, and analyzes different factors, such as gender, age, and place of residence, to compare their level differences and changing trends, and to provide data reference for the recommended intake of vitamin K2 for people with vitamin K2 deficiency.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Health, Subjective

Currently open trials in the same condition.

Other Peking University Third Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05436483.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing